Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Switch to English

10373	Sociétés
216184	Mots-clés
145886	Articles
114463	Communiqués

Accueil
Sociétés
Jaguar Health, Inc.

COMMUNIQUÉ DE PRESSE

publié le 15/12/2025 à 15:00, il y a 4 mois 26 jours

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Jaguar Health announces submission of abstract detailing preliminary findings from clinical trial on a novel oral liquid formulation of crofelemer for SBS-IF patients, supporting the focus on reducing PS needs in intestinal failure patients

Crofelemer Jaguar Health Clinical Trial SBS-IF Intestinal Failure
BRÈVE

publiée le 10/12/2025 à 15:05, il y a 5 mois

FDA Extends Conditional Approval for Jaguar Health's Canalevia-CA1

FDA Approval Veterinary Medicine Jaguar Health Canalevia-CA1 Chemotherapy In Dogs
BRÈVE

publiée le 10/12/2025 à 15:05, il y a 5 mois

La FDA prolonge l'approbation conditionnelle du Canalevia-CA1 de Jaguar Health

Jaguar Health Canalevia-CA1 Approbation De La FDA Médecine Vétérinaire Chimiothérapie Chez Les Chiens
COMMUNIQUÉ DE PRESSE

publié le 10/12/2025 à 15:00, il y a 5 mois

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health, Inc. (NASDAQ:JAGX) receives FDA renewal for Canalevia-CA1, a prescription drug for chemotherapy-induced diarrhea (CID) in dogs, with conditional approval extended until December 2026

Veterinary Medicine Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea FDA Renewal
BRÈVE

publiée le 08/12/2025 à 22:20, il y a 5 mois 1 jour

Jaguar Health annonce l'approbation de propositions lors de l'assemblée générale des actionnaires

Crofelemer Jaguar Health Approbation De La FDA Assemblée Générale Des Actionnaires Maladie À Inclusions Microvillositaires
BRÈVE

publiée le 08/12/2025 à 22:20, il y a 5 mois 1 jour

Jaguar Health Announces Approval of Proposals at Stockholder Meeting

Crofelemer Microvillus Inclusion Disease FDA Approval Jaguar Health Stockholder Meeting
COMMUNIQUÉ DE PRESSE

publié le 08/12/2025 à 22:15, il y a 5 mois 1 jour

Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders
Jaguar CEO Lisa Conte to present updates on near-term catalysts at Emerging Growth Conference; Initial results show crofelemer may extend infants' lives with MVID; Jaguar completes FDA meeting on crofelemer trial for MVID treatment

Crofelemer Jaguar Health Lisa Conte Emerging Growth Conference MVID
BRÈVE

publiée le 02/12/2025 à 15:05, il y a 5 mois 8 jours

Jaguar Health sollicite l'approbation de l'EMA pour Canalevia dans le traitement de la diarrhée canine

Jaguar Health Agence Européenne Des Médicaments Diarrhée Du Chien Approbation De Canalevia Traitement Non Antibiotique
BRÈVE

publiée le 02/12/2025 à 15:05, il y a 5 mois 8 jours

Jaguar Health Seeks EMA Approval for Canalevia to Treat Dog Diarrhea

Jaguar Health European Medicines Agency Dog Diarrhea Canalevia Approval Non-antibiotic Treatment
COMMUNIQUÉ DE PRESSE

publié le 02/12/2025 à 15:00, il y a 5 mois 8 jours

Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study
Jaguar Health, Inc. requests advice from EMA on EU approval pathway for Canalevia® in treating general diarrhea in dogs. Novel non-antibiotic approach targets a significant market gap

Jaguar Health Dogs EMA Canalevia General Diarrhea

Les Echos

Publié le 07/05/2026 à 19:15, il y a 2 jours 20 heures

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Publié le 07/05/2026 à 19:15, il y a 2 jours 20 heures

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Publié le 07/05/2026 à 19:06, il y a 2 jours 20 heures

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Publié le 07/05/2026 à 19:06, il y a 2 jours 20 heures

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Publié le 07/05/2026 à 19:00, il y a 2 jours 20 heures

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 09/05/2026 à 01:55, il y a 1 jour 13 heures

Prospect Ridge Announces Board Resignation
Publié le 09/05/2026 à 01:40, il y a 1 jour 14 heures

Findev Inc. Issues Corrective Disclosure
Publié le 09/05/2026 à 01:30, il y a 1 jour 14 heures

Star Copper Announces Agreement with Zimtu Capital Corp.
Publié le 09/05/2026 à 00:00, il y a 1 jour 15 heures

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Publié le 08/05/2026 à 23:01, il y a 1 jour 16 heures

Water Ways Announces Corporate Updates

Voir tout ACCESSWIRE

EQS Group

Publié le 10/05/2026 à 14:00, il y a 1 heure 41 minutes

MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Publié le 10/05/2026 à 11:45, il y a 3 heures 56 minutes

Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Publié le 09/05/2026 à 19:05, il y a 20 heures 36 minutes

LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Publié le 08/05/2026 à 20:38, il y a 1 jour 19 heures

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Publié le 08/05/2026 à 19:12, il y a 1 jour 20 heures

EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026